RecruitingDepression
Pharmacologic Augmentation of TMS for Depression With D-serine
Eligible age
18–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this study is to test whether combining D-serine with 30 treatments of a) iTBS and b) 18-Hz protocols will enhance clinical outcomes compared to rTMS with placebo (i.e., sugar pill). The investigators hypothesize that NMDA receptor activation via D-serine combined with repeated sessions of rTMS will produce greater clinical outcomes than iTBS with placebo and 18-Hz with placebo.
Sponsor: Mclean Hospital
You may qualify if…
- ✓ Clinical diagnosis of MDD
- ✓ English-speaking
- ✓ Adults aged 18-80
- ✓ Must be able to swallow capsules
- ✓ Relative contraindications/possible exclusion criteria:
- ✓ Containing any implanted metal or devices
- ✓ Current or previous seizure history
- ✓ Active substance use that may significantly alter the seizure threshold
You may not qualify if…
- ✕ Patients with pre-existing renal disease
- ✕ Known allergy to D-serine, or with
- ✕ Patients taking medications with known drug-drug interactions
- ✕ Children
- ✕ Pregnant or breast-feeding women
- ✕ The investigators will not include children because prior safety and dosing studies excluded children. Although considered safe for TMS, the investigators will not include pregnant or breast-feeding women on the basis of unknown safety profile of exogenous D-serine for these patients.
Where it's recruiting
Massachusetts
Belmont
Source: ClinicalTrials.gov · NCT06876129 · last updated 2026-05-15